Market LIVE
Published markets; coverage varies by country
Product profile · United States

BRILINTA

 ·  Patent Litigation & Settlement History ↓

IngredientTICAGRELOR
Application typeNDA
Application022433
Product002
Dosage formTABLET
RouteORAL
Strength60MG
Approval date2015-09-03
Marketing statusPrescription
Status event—
ApplicantASTRAZENECA
Product source

Current GenericRadar decision

Year2018
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2018-09-04
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2018-09-04
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
84259342030-04-17DP ————
———
84259342030-10-17— ————
—2030-10-17—
103000652036-01-27U U-2542———
———
103000652036-01-27U U-2541———
———
103000652036-07-27— ————
—2036-07-27—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
208390 / 001FINAL_APPROVAL · FINAL_APPROVED2018-09-04—WATSON LABORATORIES INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208597 / 001FINAL_APPROVAL · FINAL_APPROVED2021-07-09—MYLAN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208508 / 002FINAL_APPROVAL · FINAL_APPROVED2025-10-28—SUNSHINE LAKE PHARMA CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208531 / 002FINAL_APPROVAL · FINAL_APPROVED2025-10-28—AMNEAL EU LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208537 / 002FINAL_APPROVAL · FINAL_APPROVED2025-10-28—INVAGEN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208541 / 002FINAL_APPROVAL · FINAL_APPROVED2025-10-28—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208576 / 002FINAL_APPROVAL · FINAL_APPROVED2025-10-28—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208584 / 002FINAL_APPROVAL · FINAL_APPROVED2025-10-28—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208596 / 002FINAL_APPROVAL · FINAL_APPROVED2025-10-28—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210219 / 001FINAL_APPROVAL · FINAL_APPROVED2025-10-28—ALKEM LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211498 / 001FINAL_APPROVAL · FINAL_APPROVED2025-10-28—TARO PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212258 / 001FINAL_APPROVAL · FINAL_APPROVED2025-10-28—MACLEODS PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216187 / 001FINAL_APPROVAL · FINAL_APPROVED2025-10-28—CHANGZHOU PHARMACEUTICAL FACTORYNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218962 / 001FINAL_APPROVAL · FINAL_APPROVED2025-10-28—SCIEGEN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217679 / 001FINAL_APPROVAL · FINAL_APPROVED2026-02-06—MANKIND PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
219006 / 001FINAL_APPROVAL · FINAL_APPROVED2026-03-24—ZHEJIANG JINGXIN PHARMACEUTICAL CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208539 / 001FINAL_APPROVAL · FINAL_APPROVED2026-04-27—MICRO LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218869 / 001FINAL_APPROVAL · FINAL_APPROVED2026-08-20—LAURUS LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 18 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
208390 / 001WATSON LABORATORIES INCFINAL_APPROVAL · FINAL_APPROVED2018-09-04 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208597 / 001MYLAN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-07-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208508 / 002SUNSHINE LAKE PHARMA CO LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208531 / 002AMNEAL EU LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208537 / 002INVAGEN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208541 / 002DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208576 / 002ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208584 / 002APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208596 / 002MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210219 / 001ALKEM LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211498 / 001TARO PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212258 / 001MACLEODS PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216187 / 001CHANGZHOU PHARMACEUTICAL FACTORYFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218962 / 001SCIEGEN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2025-10-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217679 / 001MANKIND PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2026-02-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
219006 / 001ZHEJIANG JINGXIN PHARMACEUTICAL CO LTDFINAL_APPROVAL · FINAL_APPROVED2026-03-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208539 / 001MICRO LABS LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218869 / 001LAURUS LABS LTDFINAL_APPROVAL · FINAL_APPROVED2026-08-20 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2018-09-04TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.